Skip to main content
TCRT logo

TCRT · Alaunos Therapeutics, Inc.

Track TCRT — free
$1.66 +0.07 (+4.40%) At close · Nov 20
Market Cap
$6.99M
Shares
4.21M
Volume · Nov 20 77.56K Avg daily vol (3M) 7.44M

Price & Indicators

 

Key stats

Close
$1.66
Fri 20 Nov
Open
$1.61
Fri 20 Nov
Average volume, 30 days
14.4M
shares a session
Short interest
184K
4.4% of shares · 1.0 days to cover
Day range
$1.61$1.75
Open $1.61 Close $1.66
52-week closing range
$0.74$4.36
Close $1.66 61.9% under the high
Short volume, last session
25%
Last earnings
May 10, 2023
Latest filing
10-Q · Nov 16
Price history
Jan 2020 to Nov 2026

Up next

call held May 10, 2023

Latest documents

2026
Nov 16
Quarterly report 10-Q FY2026 Q3, ended Sep 30
VLR199 proof-of-concept data expected in 2028

Alaunos Therapeutics plans VLR199 IND or CTA submission in the second half of 2027, with proof-of-concept data expected in 2028. VLR360 also targets 2028 data, while VLR247 or VLR258 IND submission is planned for the first half of 2028.

Revenue $0 Net loss $772K Diluted EPS -$0.31
Read from the MD&A section
3 source passages
We intend to submit an IND or CTA for VLR199 in the second half of 2027 and to initiate a Phase 1 study in healthy postmenopausal women, with clinical proof-of-concept data from this study anticipated in 2028. We intend to submit an IND or CTA for VLR360 in the second half of 2027, with clinical proof-of-concept data anticipated in 2028. We intend to submit an IND or CTA for VLR247 or VLR258 in the first half of 2028. Open the document at this passage
Nov 13
Proxy statement PRE 14A
Stockholders to vote on Cayman redomestication and reverse split

Alaunos Therapeutics, Inc. asks 2027 stockholders to approve redomestication from Delaware to the Cayman Islands, a reverse split ranging from one new share for every two shares to one for every ten, and an authorized-share increase from 50,000,000 to 400,000,000.

Read from the first part of this long document
4 source passages
Notice is hereby given that a special meeting of stockholders (the “Special Meeting”) of Alaunos Therapeutics, Inc. (the “Company”) will be held virtually, via live webcast at on , 2027 at a.m. Eastern Time. Alaunos will ask its stockholders to approve (A) the redomestication of the Company from the State of Delaware to the Cayman Islands by conversion and (B)(i) the redomestication of the Company from the State of Delaware to the Cayman Islands by way of continuation and (ii) the adoption of the Cayman Articles; Alaunos will ask its stockholders to approve an amendment to its Certificate of Incorporation to increase the number of authorized shares of Common Stock from 50,000,000 to 400,000,000; Alaunos will ask its stockholders to approve an amendment to its Certificate of Incorporation to effect a reverse stock split of the issued and outstanding shares of Common Stock at a ratio of one new share for every two shares and one new share for every ten shares (or any number in between), as determined by the Board of Directors with the consent of the Lead Investor (as defined below); Open the document at this passage
Nov 13
Registration statement S-3
382,090,789 shares registered for resale by stockholders

Alaunos Therapeutics, Inc. registered up to 382,090,789 shares for resale by selling stockholders and will receive no proceeds. The registration follows the Velaris Therapeutics, Inc. acquisition closed October 13, 2026 and private placement closed October 14, 2026.

Read from the first part of this long document
5 source passages
Alaunos Therapeutics, Inc. 382,090,789 Shares Common Stock Offered by the Selling Stockholders The Merger Preferred Shares were issued to former stockholders of Velaris Therapeutics, Inc., a Delaware corporation (“Velaris”), in connection with our acquisition of Velaris (the “Asset Acquisition”), which closed on October 13, 2026. The Private Placement Shares were issued and sold to accredited investors in a private placement (the “PIPE” and, together with the Asset Acquisition, the “Transactions”), which closed on October 14, 2026. We are not offering or selling any Resale Shares under this prospectus and will not receive any of the proceeds from the sale or other disposition of Resale Shares by the Selling Stockholders. Open the document at this passage
Oct 23
Current report 8-K Events of Oct 22
Nasdaq Closes Stockholders' Equity Matter After Regained Compliance

Nasdaq confirmed that the company regained compliance with its $2,500,000 stockholders' equity requirement, so the matter is closed. The November 10, 2026 hearing before the Nasdaq Hearings Panel was cancelled, and the common stock will continue trading on The Nasdaq Capital Market.

Other events
4 source passages
the Staff has confirmed that the Company has regained compliance with the Stockholders’ Equity Requirement the hearing before the Panel scheduled for November 10, 2026 has been cancelled the Company’s common stock will continue to be listed and traded on The Nasdaq Capital Market which requires companies listed on The Nasdaq Capital Market to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing Open the document at this passage
Oct 21
Current report 8-K
Believes It Regained Nasdaq Equity Compliance After $350.0 Million Financing

Alaunos believes it regained compliance with Nasdaq's $2,500,000 stockholders' equity requirement after a financing with approximately $350.0 million gross proceeds on October 14, 2026. The November 10, 2026 hearing would be cancelled upon Staff confirmation.

Delisting notice or listing transfer
5 source passages
the Company believes that, as of the date of this Current Report on Form 8-K, it has regained compliance with the Stockholders’ Equity Requirement. which requires companies listed on The Nasdaq Capital Market to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing On October 14, 2026, the Company completed the Financing and received aggregate gross proceeds of approximately $350.0 million, before deducting placement agent fees and other offering expenses. The hearing is currently scheduled for November 10, 2026. The Company expects that, upon the Staff’s confirmation that the Company has regained compliance with the Stockholders’ Equity Requirement, the hearing before the Panel will be cancelled and the matter will be closed. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$3,000
Trailing 12 months
Net income (TTM)
−$3.62M
Trailing 12 months
Revenue growth YoY
-50.0%
Year over year
Operating margin
-121,033.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$615,000
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+19.3%
Year over year · more shares
Price change (1Y)
-53.2%
Trailing year
Short interest
4.4%
Latest settlement · 1.0 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.77
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −26%
below
Price vs 50-day avg +1%
above
RSI (14) 47
neutral
MACD trend Negative
52-week position 25%
mid-range
Momentum
relative strength
Very Weak
1-month return −27%
trailing
6-month return −40%
trailing
YTD return −49%
this year
Relative strength −30%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Accumulating
+10% holders QoQ · +6 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
4.38% of shares out · ▼ -77.5% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
32 holders — mid 3-yr range
Squeeze score 43
elevated · 0–100
Fundamentals
Strong
Revenue growth +1888%
Y/Y
EPS growth +25%
Y/Y
Free cash flow $-3.0M
Balance sheet $1.4M
net cash
Quant / Vol
risk profile
Very High
Volatility 215%
annualized · 1-yr
Max drawdown −83%
past year
ATR 15.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
2 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−26% Bearish
Price vs 50-day avg
+1% Bullish
RSI (14)
47 Neutral
MACD trend
Negative Bearish
52-week position
25% Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Accumulating
+10% holders QoQ · +6 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
4.38% of shares out · ▼ -77.5% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
32 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $2 · 25% Range high $4
vs 200-day avg -26% vs 50-day avg +1%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
TCRT
Alaunos Therapeutics, Inc.
this stock
$6.99M -48.6% -50.0% — 4.4%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
32
% held
4.0%
Net QoQ
+80.0K sh
Top holder
Integrated Wealth Concept…
Held Float
View
Held by Funds
Fund positions
9
View
Short & Settlement
Short Interest Falling
Shares short
184.4K
Days to cover
1.0d
Change
-634.2K sh
View
Short Volume
Short vol %
25%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
4.1K
Value
$7.7K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
64.5%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$5.0K
Net income (FY)
$-4.2M
EPS diluted
$-2.20
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 16, 2026
This year
19

Alaunos Therapeutics plans VLR199 IND or CTA submission in the second half of 2027, with proof-of-concept data expected in 2028. VLR360 also targets 2028 data, while VLR247 or VLR258 IND submission is planned for the first half of 2028.

View
Proposed Sales
Value
$6.5K
Shares
3.0K
Filed
Dec 31, 2024
View
Earnings & Events
Webcasts
Last webcast
Nov 18, 2026
View
Investor Relations
Latest news
Alaunos Therapeutics and its Subs…
Published
Nov 2, 2026
View

Performance

5D 20D 120D MTD YTD
TCRT +1.8% -27.2% -39.6% -14.9% -48.6%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY +10.4% -18.0% -30.5% -6.2% -49.8%
Key facts CIK 1107421 CUSIP 98973P309 13F (30d) 39 filings 30 filers Visit website Investor relations